financetom
Business
financetom
/
Business
/
Lowe's, Home Depot Comparable Sales Weakness to Persist Near Term, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lowe's, Home Depot Comparable Sales Weakness to Persist Near Term, Oppenheimer Says
Sep 25, 2024 5:14 PM

11:23 AM EDT, 09/24/2024 (MT Newswires) -- Home improvement retailers Lowe's (LOW) and Home Depot ( HD ) likely won't return to positive comparable sales growth until the second half of 2025 as it may take substantial time for reduced interest rates to buoy consumer spending, Oppenheimer said Tuesday.

Same-store sales for the two companies are expected to remain in negative territory through the first half of 2025 due to "post-pandemic demand dislocations in the sector and potentially delayed benefits of moderating rates," according to a group of Oppenheimer analysts, including Brian Nagel.

Last week, the Federal Reserve reduced benchmark rates by 50 basis points.

Investors are likely to look through near-term fundamental weakness at the chains, with sales expected to strengthen in 2025, Nagel said. Moderating interest rates tend to "underpin stronger demand for home-related items, but often with a substantial lag," according to the Oppenheimer note.

Oppenheimer upgraded Lowe's to outperform from perform and raised its price target to $305 from $230. Home Depot's ( HD ) target was raised to $400 from $345 while Nagel reiterated a perform rating.

For fiscal 2025, the analysts lowered their forecast for Lowe's earnings per share to $11.85 from $13.10, putting Oppenheimer below the $12.66 consensus. The brokerage is modeling fiscal 2026 EPS of $13.30, below Wall Street's $13.82 view.

For Home Depot ( HD ), Oppenheimer reduced its fiscal 2025 EPS forecast to $14.93 from $15.70, putting it below the $15.67 consensus. It is modeling fiscal 2026 EPS of $15.99, below the market's $17.06 estimate.

There remains a potential for downside risk to Street forecasts over the near term, Nagel wrote.

Price: 264.82, Change: +2.52, Percent Change: +0.96

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Canada to assess toxicity of compound found in oil sands tailings
Canada to assess toxicity of compound found in oil sands tailings
May 30, 2024
May 30 (Reuters) - Canada has agreed to assess whether naphthenic acids found in northern Alberta's oil sands tailings ponds should be classed as toxic under federal law, a move that could pave the way for stricter regulations, environmental group Ecojustice said on Thursday. Tailings - a mix of water, clay, sand and trace metals - are a byproduct of...
EXPLAINER-What to know about bird flu in dairy cows and the risk to humans
EXPLAINER-What to know about bird flu in dairy cows and the risk to humans
May 30, 2024
(Adds details on third human case in paragraph 1, 2; updates throughout) By Julie Steenhuysen CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found...
HP Stock Makes Historic Move Higher: What's Going On?
HP Stock Makes Historic Move Higher: What's Going On?
May 30, 2024
HP Inc. ( HPQ ) experienced a historic stock surge Thursday afternoon, with shares climbing as much as 19% — the largest one-day gain since 1999 — following the release of its second-quarter financial results. What Happened: HP shares jumped after the tech giant reported net revenue of $12.8 billion, above the consensus estimate of $12.6 billion. Adjusted EPS rose...
Summit Therapeutics' Ivonescimab Beats Merck's Therapy in Lung Cancer -- Shares Soar
Summit Therapeutics' Ivonescimab Beats Merck's Therapy in Lung Cancer -- Shares Soar
May 30, 2024
03:46 PM EDT, 05/30/2024 (MT Newswires) -- Summit Therapeutics ( SMMT ) shares soared 137% in recent trading Thursday after the company shared results of ivonescimab meeting primary endpoint of progression-free survival to treat a type of lung cancer, beating Merck's ( MRK ) pembrolizumab. Results from the phase 3 trial showed that ivonescimab was statistically better at improving progression-free...
Copyright 2023-2026 - www.financetom.com All Rights Reserved